Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 suggestions for treating power myeloid leukemia. Leukemia. 2020;34:966–84.
Patel AB, O’Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in power myeloid leukemia and the event of subsequent era ABL kinase inhibitors. Hematol Oncol Clin N Am. 2017;31:589–612.
Cortes J, Lang F. Third-line remedy for power myeloid leukemia: present standing and future instructions. J Hematol Oncol. 2021;14:44.
Akard LP, Albitar M, Hill CE, Pinilla-Ibarz J. The “hit exhausting and hit early” method to the therapy of power myeloid leukemia: implications of the up to date Nationwide Complete Most cancers Community medical follow tips for routine follow. Clin Adv Hematol Oncol. 2013;11:421–32.
Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors within the therapy of power myeloid leukemia: an evolving therapy paradigm. Clin Lymphoma Myeloma Leuk. 2015;15:323–34.
Bosi GR, Fogliatto LM, Costa TEV, Grokoski KC, Pereira MP, Bugs N, et al. What occurs to illiberal, relapsed or refractory power myeloid leukemia sufferers with out entry to medical trials? Hematol Transfus Cell Ther. 2019;41:222–8.
Jabbour E, Parikh SA, Kantarjian H, Cortes J. Continual myeloid leukemia: mechanisms of resistance and therapy. Hematol Oncol Clin N Am. 2011;25:981–95.
Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in power section power myelogenous leukemia sufferers immune to tyrosine kinase inhibitors, in a matched pair evaluation. Haematologica. 2013;98:1510–6.
Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in power myeloid leukemia. Leuk Res. 2014;38:10–20.
Dhillon S. Olverembatinib: first approval. Medicine. 2022;82:469–75.
Gorre ME, Mohammed M, Ellwood Okay, Hsu N, Paquette R, Rao PN, et al. Scientific resistance to STI-571 most cancers remedy brought on by BCR-ABL gene mutation or amplification. Science. 2001;293:876–80.
Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a possible therapy for power myeloid leukemia, as a myristate-pocket binding ABL inhibitor and evaluation of its interactions with mutant types of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and security in Philadelphia chromosome-positive leukemia: ultimate 5-year outcomes of the section 2 PACE trial. Blood. 2018;132:393–404.
Deininger MW, Apperley JF, Arthur CK, Chuah C, Hochhaus A, De Lavallade H, et al. Put up hoc evaluation of responses to ponatinib in sufferers with chronic-phase power myeloid leukemia (CP-CML) By baseline BCR-ABL1 stage and baseline mutation standing within the OPTIC Trial. Blood. 2021;138:307.
Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, et al. Life after ponatinib failure: outcomes of power and accelerated section CML sufferers who discontinued ponatinib within the salvage setting. Leuk Lymphoma. 2018;59:1312–22.
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging examine in chronic-phase power myeloid leukemia: a randomized, open-label section 2 medical trial. Blood. 2021;138:2042–50.
Molica M, Scalzulli E, Colafigli G, Foa R, Breccia M. Insights into the optimum use of ponatinib in sufferers with power section power myeloid leukaemia. Ther Adv Hematol. 2019;10:2040620719826444.
Iclusig (Ponatinib) [package insert]. Cambridge MTPCL.
Jabbour E, Kantarjian H, O’Brien S, Shan J, Quintas-Cardama A, Faderl S, et al. The achievement of an early full cytogenetic response is a significant determinant for final result in sufferers with early power section power myeloid leukemia handled with tyrosine kinase inhibitors. Blood. 2011;118:4541–6.
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly recognized power myeloid leukemia. J Clin Oncol. 2011;29:1634–42.
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, et al. Dose modification dynamics of ponatinib in sufferers with chronic-phase power myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024;38:475–81.
Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase exercise of BCR-ABL1. J Med Chem. 2018;61:8120–35.
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Bathroom A, Furet P, et al. The allosteric inhibitor ABL001 permits twin focusing on of BCR-ABL1. Nature. 2017;543:733–7.
Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A section 3, open-label, randomized examine of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or extra prior TKIs. Blood. 2021;138:2031–41.
Mauro MJ, Hughes TP, Kim D-W, Réa D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in sufferers with CML-CP with out BCR::ABL1 T315I mutations handled with a minimum of two prior TKIs: 4-Yr section 1 security and efficacy outcomes. Leukemia. 2023;37:1048–59.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in power myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–26.
Novartis Prescription drugs Company. NDA/BLA Multi-disciplinary Evaluation and Analysis {NDA 215358} SCEMBLIX (asciminib). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000MultidisciplineR.pdf. Accessed 29 Apr 2024.
Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB. Publicity-efficacy evaluation of asciminib in Philadelphia chromosome-positive power myeloid leukemia in power section. Clin Pharmacol Ther. 2022;112:1040–50.
Scemblix (asciminib) [package insert]. East Hanover, NJ; Novartis Pharmaceutical Company. 2023.
Hughes TP, Cortes JE, Réa D, Mauro MJ, Hochhaus A, Kim D-W, et al. Asciminib supplies sturdy molecular responses in sufferers with power myeloid leukemia in power section (CML-CP) with the T315I mutation: up to date efficacy and security information from a section I trial. Introduced at: EHA2022 Congress; June 9-17, 2022; Vienna, Austria, and On-line. Poster P704.
Scemblix (asciminib) [prescribing information]. Macquarie Park N, Australia; Novartis Prescription drugs Australia Pty Restricted; 2022.
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Continual myeloid leukemia: an replace of ideas and administration suggestions of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Lengthy-term final result of power myeloid leukemia sufferers handled frontline with imatinib. Leukemia. 2015;29:1823–31.
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. 5-year follow-up of sufferers receiving imatinib for power myeloid leukemia. N Engl J Med. 2006;355:2408–17.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A section 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Evaluation of imatinib as first-line therapy of power myeloid leukemia: 10-year survival outcomes of the randomized CML examine IV and influence of non-CML determinants. Leukemia. 2017;31:2398–406.
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, et al. Early response with dasatinib or imatinib in power myeloid leukemia: 3-year follow-up from a randomized section 3 trial (DASISION). Blood. 2014;123:494–500.
Cortes J, Quintas-Cardama A, Kantarjian HM. Monitoring molecular response in power myeloid leukemia. Most cancers. 2011;117:1113–22.
Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by nearly all of sufferers handled with imatinib, predicts survival, and is achieved extra shortly by optimized high-dose imatinib: outcomes from the randomized CML-study IV. J Clin Oncol. 2014;32:415–23.
Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O’Brien S, et al. Significance of deeper molecular responses in sufferers with power myeloid leukemia in early power section handled with tyrosine kinase inhibitors. Am J Hematol. 2013;88:1024–9.
Garcia-Horton A, Lipton JH. Remedy outcomes in power myeloid leukemia: does one measurement match all? J Natl Compr Canc Netw. 2020;18:1421–8.
Etienne G, Dulucq S, Nicolini FE, Morrisset S, Fort MP, Schmitt A, et al. Attaining deeper molecular response is related to a greater medical final result in power myeloid leukemia sufferers on imatinib front-line remedy. Haematologica. 2014;99:458–64.
Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase power myeloid leukemia beforehand handled with a minimum of two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617–26.
Santoro M, Mancuso S, Accurso V, Di Lisi D, Novo G, Siragusa S. Cardiovascular points in tyrosine kinase inhibitors therapies for power myeloid leukemia: a evaluate. Entrance Physiol. 2021;12:675811.
Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors utilized in power myeloid leukemia: an evaluation of the FDA opposed occasion reporting system database (FAERS). Cancers. 2020;12:826.
Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in power myeloid leukemia: preventive methods and cardiovascular surveillance. Vasc Well being Threat Manag. 2017;13:293–303.
Gleevec (imatinib) [package insert]. East Hanover, NJ; Novartis Prescription drugs Company. 2024.
Tasigna (nilotinib) [package insert]. East Hanover, NJ; Novartis Prescription drugs Company. 2024.
Sprycel (dasatinib) [package insert]. Princeton, NJ; Bristol-Myers Squibb Firm. 2023.
Bosulif (bosutinib) [package insert]. New York, NY; Pfizer Labs. 2023.
Singh AP, Glennon MS, Umbarkar P, Gupte M, Galindo CL, Zhang Q, et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue methods. Cardiovasc Res. 2019;115:966–77.
Cheng S, Jin P, Li H, Pei D, Shu X. Analysis of CML TKI induced cardiovascular toxicity and growth of potential rescue methods in a zebrafish mannequin. Entrance Pharmacol. 2021;12:740529.
Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong ASM, et al. Glorious early and main molecular responses noticed with asciminib therapy for CP-CML: outcomes from the ALLG CML13 Ascend-CML examine. Presentation at: sixty fifth ASH Annual Assembly and Exposition; December 9-12, 2023; San Diego, CA, & On-line. Summary P704.
Réa D, Hochhaus A, Mauro MJ, Minami Y, Lomaia E, Voloshin S, et al. Efficacy and security outcomes from ASCEMBL, a section 3 examine of asciminib vs bosutinib in sufferers with power myeloid leukemia in power section after =/>2 prior tyrosine kinase inhibitors: wk 96 replace. Introduced at: EHA2022 Congress; June 9-17, 2022; Vienna, Austria, and On-line. Summary S155.
Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A section 3, open-label, randomized examine of asciminib, a STAMP inhibitor, vs bosutinib in CML after >/=2 prior TKIs. Blood. 2021;138:2031–41.
Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet suggestions for the administration and avoidance of opposed occasions of therapy in power myeloid leukaemia. Leukemia. 2016;30:1648–71.
Rea D. Administration of opposed occasions related to tyrosine kinase inhibitors in power myeloid leukemia. Ann Hematol. 2015;94:S149–58.
Luna A, Perez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuno C, et al. Actual-life evaluation on security and efficacy of asciminib for ponatinib pretreated sufferers with power myeloid leukemia. Ann Hematol. 2022;101:2263–70.
